Browse December's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.
The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with RA at high CV risk, show the ORAL Surveillance results.
Olokizumab shows clinical and physical benefits for patients with rheumatoid arthritis (RA) with inadequate responses to methotrexate and tumor necrosis inhibitor (TNF) inhibitor therapy in the latest CREDO findings. Read now
In “The Great Debate”, experts discussed which new add-on treatment option should be used first for patients with active lupus nephritis despite conventional therapy. Read now
Individuals with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis have almost comparable survival rates to those of the general population, Greek study findings indicate.
The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with rheumatoid arthritis at high cardiovascular risk, show the ORAL Surveillance results.
TNF inhibitor monotherapy is associated with a lower risk for COVID-19-related hospitalization or death than other common immunomodulatory treatments given to people with immune-mediated inflammatory diseases, research suggests.
